---
title: "TG Therapeutics, Inc. (TGTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TGTX.US.md"
symbol: "TGTX.US"
name: "TG Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-06-10T16:29:39.218Z"
locales:
  - [en](https://longbridge.com/en/quote/TGTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TGTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TGTX.US.md)
---

# TG Therapeutics, Inc. (TGTX.US)

## Company Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.tgtherapeutics.com](https://www.tgtherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-10T04:30:18.000Z

**Overall: B (0.30)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 22 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 81.26% |  |
| Net Profit YoY | 1079.81% |  |
| P/B Ratio | 11.88 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6925679662.72 |  |
| Revenue | 700349000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 112.60% | A |
| Profit Margin | 65.95% | A |
| Gross Margin | 83.65% | A |
| Revenue YoY | 81.26% | A |
| Net Profit YoY | 1079.81% | A |
| Total Assets YoY | 132.81% | A |
| Net Assets YoY | 145.75% | A |
| Cash Flow Margin | -3.02% | D |
| OCF YoY | 81.26% | A |
| Turnover | 0.64 | B |
| Gearing Ratio | 61.86% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - TG Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "81.26%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "1079.81%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "11.88",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6925679662.72",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "700349000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "112.60%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "65.95%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "83.65%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "81.26%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "1079.81%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "132.81%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "145.75%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-3.02%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "81.26%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.64",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "61.86%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.99 | 31/390 | 84.58 | 13.08 | 10.31 |
| PB | 11.88 | 402/390 | 18.50 | 10.03 | 7.48 |
| PS (TTM) | 9.89 | 163/390 | 11.26 | 9.10 | 8.48 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-09T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 67% |
| Overweight | 1 | 11% |
| Hold | 1 | 11% |
| Underweight | 1 | 11% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 47.32 |
| Highest Target | 70.00 |
| Lowest Target | 17.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TGTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TGTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TGTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TGTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**